Supplemental material
Expert Review of Vaccines
Volume 21, 2022 - Issue 10
Original Research
Predicting effectiveness of the V114 vaccine against invasive pneumococcal disease in children
Josiah Rymana Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc, Rahway, NJ, USA
https://orcid.org/0000-0002-7692-4432View further author information
https://orcid.org/0000-0002-7692-4432View further author information, Jessica Weaverb Center for Observational and Real-World Evidence, Merck & Co., Inc, Rahway, NJ, USACorrespondence[email protected]
https://orcid.org/0000-0002-9861-3328View further author information
https://orcid.org/0000-0002-9861-3328View further author information, Ka Lai Yeea Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc, Rahway, NJ, USAhttps://orcid.org/0000-0003-3099-4440View further author information
https://orcid.org/0000-0003-3099-4440View further author information & Jeffrey R. Sachsa Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc, Rahway, NJ, USAhttps://orcid.org/0000-0001-5725-558XView further author information
https://orcid.org/0000-0001-5725-558XView further author information